People with diverse immunogenetic backgrounds may be ableto respond to the HGP-30 candidate AIDS vaccine, according toa recent article in Biomedicine and Pharmacotherapy.
A study reported in the latest issue of the French publicationsuggests the candidate vaccine contains broadly reactiveepitopes and is not HLA class II restricted, as are many peptidevaccines.
The study was conducted in blood samples of 40 HIV-positivepeople at the Universite Pierre et Marie Curie and Hospital St.Antoine in Paris. HGP-30 has been shown to be safe andimmunogenic in two clinical trials of healthy HIV-negativeindividuals.
Patent rights to HGP-30 are owned by Bethesda, Md.-basedViral Technologies Inc., a joint venture of Cel-Sci Corp.(NASDAQ:CELI) and Alpha 1 Biomedicals Inc. (NASDAQ:ALBM).
(c) 1997 American Health Consultants. All rights reserved.